CRO龙头,2.7亿内部大洗牌

药圈观察局
Yesterday

看之前记得先点个关注,欢迎投稿共创。药圈观察局,最新观察:‌本文为共创内容,作者:#药圈观察局1组据悉,临床CRO龙头泰格医药其历时近五个月的内部资产重组正式落定。泰格医药以2.7亿元人民币的对价,将旗下临床实验服务公司上海观合医药的全部股权,出售给同属集团旗下的子公司方达医药。买方方达医药技术是方达控股的全资子公司,而方达控股本身就是泰格医药的上市子公司。(方达集团主要从事贯穿产品发现及开发过程...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10